Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
J. Bienzeisler,
A. Kombeiz,
S. Ehrentreich,
R. Otto,
W. Schirrmeister,
M. Pegoraro,
D. Brammen,
B. Puladi,
R. Röhrig and
R. W. Majeed,
"Implementation report on pioneering federated data access for the German National Emergency Department Data Registry",
NPJ Digit Med,
vol. 1,
no. 94,
02
2025.
| DOI: | 10.1038/s41746-025-01481-w |
| Pubmed: | 39934366 |
C. Bartenschlager,
R. Frey,
M. Freitag and
et al,
"Managing hospital visitor admission during Covid-19: A discrete-event simulation by the data of a German University Hospital".
Gehalten auf der Hawaii International Conference on System Sciences 2022.
| DOI: | 10.24251/HICSS.2022.449 |
K. O. Yusuf,
S. Hanss and
D. Krefting,
"Towards a Consistent Representation of Contradictions Within Health Data for Efficient Implementation of Data Quality Assessments.",
Studies in Health Technology and Informatics, eBook Serie,
vol. 302.
B. Lorenz-Depiereux,
S. Hopff,
H. Valentin,
M. Scherer,
S. Berger,
G. Anton,
B. Balzuweit,
T. Bahmer,
T. Illig,
A. Blumentritt,
C. Schäfer,
S. Hanss,
M. Nauck,
D. Krefting,
S. Schreiber,
M. Witzenrath,
J. Schaller,
W. Lieb,
D. Stahl,
J. Vehreschild,
M. Kraus,
On Behalf Of The Napkon Study Group and
N. Ethics Coordination,
"Poster Biobank-Symposium: Ethik-Koordination in NUKLEUS am Beispiel von NAPKON – Herausforderungen und Chancen".
M. Kraus,
C. Hampf,
T. Bahls,
W. Hoffmann,
M. Bialke,
A. Blumentritt,
F. Moser,
S. Lang,
E. Sargsyan and
A. Stehn,
"Poster Biobank-Symposium: Semantic Consent Code (SCC) Optionen für mehr Einheitlichkeit bei der Codierung und Abfrage von Einwilligungsinhalten".
C. Klein,
M. Borsche,
A. Balck and
et al,
"One-year surveillance of SARS-CoV-2 transmission of the ELISA Cohort: A model for population-based monitoring of infection risk",
Science Adv.
M. Jukic,
A. Dunkel,
B. Haller and
et al,
"Persistent loss of smell and taste perception in subjects with anti-SARS-CoV-2 antibodies".
M. Kahn,
S. Zellmer,
A. Ebigbo and
et al,
"Progress of the vaccination campaign among HCW in AGP in Germany".
A. Wulff,
P. Biermann,
T. Landesberger and
et al,
"A Smart Infection Control System for COVID-19 Infections in Hospitals"
in Conference on 66. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS) 2021.
| Datei: | https://www.egms.de/static/de/meetings/gmds2021/21gmds058.shtml |
A. Wulff,
P. Biermann,
T. Landesberger and
et al,
"Tracing COVID-19 infection chains within healthcare institutions: Another brick in the wall against SARS-CoV-2"
in MedInfo Conference 2021.
| Datei: | https://imia-medinfo.org/medinfo21/ |
S. Kugai,
B. Aretz,
Y. Krumpholtz,
M. Schmidt,
D. Süssle,
L. Steyer,
A. Henkel,
K. Bender,
F. Girrbach,
S. Stehr,
K. Balzer and
B. Weltermann,
"Innovative Regional Services and Heterogeneous Communication Channels: Results from the Nationwide German egePan Project for Pandemic Management",
Healthcare,
vol. 21,
no. 21,
pp. 2192,
Nov.
2024.
| DOI: | 10.3390/healthcare12212192 |
K. Appel,
C. Lee,
S. N. Miranda,
D. Maier,
J. Reese,
G. Anton,
T. Bahmer,
S. Ballhausen,
B. Balzuweit,
C. Bellinghausen,
A. Blumentritt,
M. Brechtel,
I. Chaplinskaya-Sobol,
J. Erber,
K. Fiedler,
R. Geisler,
R. Heyder,
T. Illig,
M. Kohls,
L. Krist,
R. Lorbeer,
O. Miljukov,
L. Mitrov,
C. Nürnberger,
C. Pape,
C. Pley,
C. Schäfer,
J. Schaller,
M. Schattschneider,
M. Scherer,
N. Schulze,
D. Stahl,
H. C. Stubbe,
T. Tamminga,
J. J. Tebbe,
M. Vehreschild,
J. J. Vehreschild,
S. Wiedmann and
J. Kollek,
"A precise performance-based reimbursement model for the multi-centre NAPKON cohorts - development and evaluation",
Sci Rep. 2024 Jun 13;14(1):13607,
06
2024.
| DOI: | 10.1038/s41598-024-63945-5 |
| Pubmed: | 38871878 |
C. Stellmach,
S. Hopff,
T. Jaenisch,
S. N. Miranda,
E. Rinaldi,
N. group,
L.,
O. and
R. Working Groups,
"Creation of Standardized Common Data Elements for Diagnostic Tests in Infectious Disease Studies: Semantic and Syntactic Mapping",
J Med Internet Res. 2024 Jun 10;26:e50049,
06
2024.
| DOI: | 10.2196/50049 |
Y. Devaux,
L. Zhang,
A. Lumley,
K. Karaduzovic-Hadziabdic,
V. Mooser,
S. Rousseau,
M. Shoaib,
V. Satagopam,
M. Adilovic,
P. Srivastava,
C. Emanueli,
F. Martelli,
S. Greco,
L. Badimon,
T. Padro,
M. Lustrek,
M. Scholz,
M. Rosolowski,
T. Brandenburger,
J. J. Vehreschild,
B. Lorenz-Depiereux,
M. Dörr,
O. Witzke,
M. Jordan,
B. Benczik,
B. Agg,
P. Ferdinandy,
G. Sanchez,
S. Kul,
A. Baker,
G. Fagherazzi,
M. Ollert,
R. Wereski,
N. Mills and
H. Firat,
"Development of a long noncoding RNA-based machine learning model to predict COVID-19 in-hospital mortality",
Nat Commun. 2024 May 20; 15(1):4259.,
05
2024.
S. Hopff,
K. Appel,
O. Miljukov,
J. Schneider,
M. Addo,
S. Bercker,
S. Blaschke,
I. Bröhl,
H. Dashti,
J. Erber,
A. Friedrichs,
R. Geisler,
S. Göpel,
M. Hagen,
F. Hanses,
B. Jensen,
A. Krawczyk,
B. Lorenz-Depiereux,
P. Meybohm,
M. Milovanovic,
L. Mitrov,
C. Nürnberger,
C. Römmele,
C. Schäfer,
C. Scheer,
M. Scherer,
J. Schmidt,
K. Seibel,
S. Sikdar,
J. J. Tebbe,
P. R. Tepasse,
M. Vehreschild,
C. Weismantel,
J. J. Vehreschild,
R. Bals,
N. Büchner,
M. Keul,
W. Obst and
P. Thelen,
"Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron-results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP)",
Infection. 2024 May 3,
05
2024.
| DOI: | 10.1007/s15010-024-02270-5 |
J. Bienzeisler,
G. Becker,
B. Erdmann,
A. Kombeiz,
R. W. Majeed,
R. Röhrig,
F. Greiner,
R. Otto,
F. Otto-Sobotka and
AKTIN Research Group,
"The Effects of Displaying the Time Targets of the Manchester Triage System to Emergency Department Personnel: Prospective Crossover Study",
J Med Internet Res,
vol. 26,
Mai
2024.
| DOI: | 10.2196/45593 |
| Pubmed: | 38743464 |
[de]
S. Windeck,
K. Allgoewer,
S. Stillfried,
L. Triefenbach,
U. Nienaber,
R. D. Bülow,
R. Röhrig,
B. Ondruschka,
P. Boor and
NATON,
"[Development and progress of the National Autopsy Network
(NATON)]",
Pathologie (Heidelb),
vol. Online ahead of print,
2024.
Abstract:
BACKGROUND: Autopsies have long been considered the gold standard for quality assurance in medicine, yet their significance in basic research has been relatively overlooked. The COVID-19 pandemic underscored the potential of autopsies in understanding pathophysiology, therapy, and disease management. In response, the German Registry for COVID-19 Autopsies (DeRegCOVID) was established in April 2020, followed by the DEFEAT PANDEMIcs consortium (2020-2021), which evolved into the National Autopsy Network (NATON). DEREGCOVID: DeRegCOVID collected and analyzed autopsy data from COVID-19 deceased in Germany over three years, serving as the largest national multicenter autopsy study. Results identified crucial factors in severe/fatal cases, such as pulmonary vascular thromboemboli and the intricate virus-immune interplay. DeRegCOVID served as a central hub for data analysis, research inquiries, and public communication, playing a vital role in informing policy changes and responding to health authorities. NATON: Initiated by the Network University Medicine (NUM), NATON emerged as a sustainable infrastructure for autopsy-based research. NATON aims to provide a data and method platform, fostering collaboration across pathology, neuropathology, and legal medicine. Its structure supports a swift feedback loop between research, patient care, and pandemic management. CONCLUSION: DeRegCOVID has significantly contributed to understanding COVID-19 pathophysiology, leading to the establishment of NATON. The National Autopsy Registry (NAREG), as its successor, embodies a modular and adaptable approach, aiming to enhance autopsy-based research collaboration nationally and, potentially, internationally.
| DOI: | https://doi.org/10.1007/s00292-024-01307-8 |
Abstract:
BACKGROUND: Autopsies have long been considered the gold standard for quality assurance in medicine, yet their significance in basic research has been relatively overlooked. The COVID-19 pandemic underscored the potential of autopsies in understanding pathophysiology, therapy, and disease management. In response, the German Registry for COVID-19 Autopsies (DeRegCOVID) was established in April 2020, followed by the DEFEAT PANDEMIcs consortium (2020-2021), which evolved into the National Autopsy Network (NATON). DEREGCOVID: DeRegCOVID collected and analyzed autopsy data from COVID-19 deceased in Germany over three years, serving as the largest national multicenter autopsy study. Results identified crucial factors in severe/fatal cases, such as pulmonary vascular thromboemboli and the intricate virus-immune interplay. DeRegCOVID served as a central hub for data analysis, research inquiries, and public communication, playing a vital role in informing policy changes and responding to health authorities. NATON: Initiated by the Network University Medicine (NUM), NATON emerged as a sustainable infrastructure for autopsy-based research. NATON aims to provide a data and method platform, fostering collaboration across pathology, neuropathology, and legal medicine. Its structure supports a swift feedback loop between research, patient care, and pandemic management. CONCLUSION: DeRegCOVID has significantly contributed to understanding COVID-19 pathophysiology, leading to the establishment of NATON. The National Autopsy Registry (NAREG), as its successor, embodies a modular and adaptable approach, aiming to enhance autopsy-based research collaboration nationally and, potentially, internationally.
[en]
K. S. Appel,
C. Nürnberger,
T. Bahmer,
C. Förster,
M. C. Polidori,
M. Kohls,
T. Kraus,
N. Hettich-Damm,
J. Petersen,
S. Blaschke,
I. Bröhl,
J. Butzmann,
H. Dashti,
J. Deckert,
M. Dreher,
K. Fiedler,
C. Finke,
R. Geisler,
F. Hanses,
S. M. Hopff,
B. O. Jensen,
M. Konik,
K. Lehnert,
S. M. N. Miranda,
L. Mitrov,
O. Miljukov,
J. Reese,
G. Rohde,
M. Scherer,
K. Tausche,
J. J. Tebbe,
J. J. Vehreschild,
F. Voit,
P. Wagner,
M. Weigl,
C. Lemhöfer,
K. Alsaad,
E. Hamelmann,
H. Heidenreich,
C. Hornberg,
N. S. A. Kulamadayil-Heidenreich,
P. Maasjosthusmann,
A. Muna,
M. Ruwe,
C. Stellbrink,
N. Buechner,
Y. Dashti,
C. Tessmer,
B. Laumerich,
I. Silberbaur,
S. Bader,
M. Engelmann,
A. Fuchs,
A. Langer,
B. Maerkl,
H. Messmann,
A. Muzalyova,
C. Roemmele,
H. Altmann,
R. Berner,
S. Dressen,
T. Koch,
D. Lindemann,
K. Seele,
P. Spieth,
N. Toepfner,
S. V. Bonin,
T. Feldt,
V. Keitel,
A. Killer,
L. Knopp,
T. Luedde,
M. Lutterbeck,
M. Paluschinski,
J. P. V. Pereira,
J. Timm,
D. Kraska,
A. E. Kremer,
M. Leppkes,
J. Mang,
M. F. Neurath,
H. U. Prokosch,
J. Schmid,
M. Vetter,
C. Willam,
K. Wolf,
C. Arendt,
C. Bellinghausen,
S. Cremer,
A. Groh,
A. Gruenewaldt,
Y. Khodamoradi,
S. Klinsing,
M. Vehreschild,
T. Vogl,
M. Addo,
M. Almahfoud,
A. L. F. Engels,
D. Jarczak,
M. Kerinn,
S. Kluge,
R. Kobbe,
S. Petereit,
C. Schlesner,
T. Zeller,
R. Baber,
S. Bercker,
N. Krug,
S. D. Mueller,
H. Wirtz,
G. Boeckel,
J. A. Meier,
T. Nowacki,
P. R. Tepasse,
R. Vollenberg,
C. Wilms,
E. Dahl,
N. Marx,
D. Mueller-Wieland,
J. Wipperfuerth,
C. Brochhausen-Delius,
R. Burkhardt,
M. Feustel,
O. Haag,
S. Hansch,
M. Malfertheiner,
T. Niedermair,
P. Schuster,
S. Wallner,
W. Barkey,
J. Erber,
L. Fricke,
J. Lieb,
T. Michler,
L. Mueller,
C. Spinner,
C. Winter,
M. Bitzer,
S. Bunk,
S. Göpel,
H. Haeberle,
K. Kienzle,
H. Mahrhofer,
N. Malek,
P. Rosenberger,
C. Struemper,
F. Trauner,
S. Frantz,
A. Frey,
K. Haas,
C. Haertel,
J. Herrmann,
N. Isberner,
J. Liese,
P. Meybohm,
J. Schmidt,
P. Schulze,
F. Brinkmann,
Y. Brueggemann,
T. Gambichler,
K. Hellwig,
T. Luecke,
A. Reinacher-Schick,
W. E. Schmidt,
C. Schuette,
E. Steinmann,
C. Torres Reyes,
A. Hafke,
G. Hermanns,
S. Y. Nussbeck,
M. Santibanez-Santana,
S. Zeh,
L. Brochhagen,
S. Dolff,
C. Elsner,
A. Krawczyk,
R. J. Madel,
M. Otte,
O. Witzke,
K. Becker,
M. Doerr,
N. Piasta,
E. Schaefer,
C. Scheer,
A. Arlt,
F. Griesinger,
U. Guenther,
A. Hamprecht,
K. Juergens,
A. Kluge,
C. Meinhardt,
K. Meinhardt,
A. Petersmann,
R. Prenzel,
M. Brechtel,
M. Laugwitz,
C. Lee,
G. Sauer,
N. Schulze,
K. Seibel,
M. Stecher,
M. Hagen,
S. Sikdar,
C. Weismantel,
L. Wolf,
K. Günther,
J. Haug,
F. Haug,
C. Fiessler,
P. U. Heuschmann,
L. Schmidbauer,
S. Jiru-Hillmann,
T. Bahls,
H. Valentin,
I. Chaplinskaya,
S. Hanß,
D. Krefting,
C. Pape,
M. Rainers,
A. Schoneberg,
N. Weinert,
M. Kraus,
B. Lorenz-Depiereux,
R. Lorbeer,
J. Schaller,
J. Fricke,
L. Krist,
M. Rönnefarth,
S. Schmidt,
T. Bahmer,
A. Hermes,
M. Krawczak,
W. Lieb,
T. Tamminga,
S. Herold,
P. Heuschmann,
R. Heyder,
T. Illig,
M. Witzenrath and
Group,
"Definition of the Post-COVID syndrome using a symptom-based
Post-COVID score in a prospective, multi-center,
cross-sectoral cohort of the German National Pandemic Cohort
Network (NAPKON)",
Infection,
Apr.
2024.
Springer Science and Business Media LLC.
Abstract:
Abstract Purpose The objective examination of the Post-COVID syndrome (PCS) remains difficult due to heterogeneous definitions and clinical phenotypes. The aim of the study was to verify the functionality and correlates of a recently developed PCS score. Methods The PCS score was applied to the prospective, multi-center cross-sectoral cohort (in- and outpatients with SARS-CoV-2 infection) of the "National Pandemic Cohort Network (NAPKON, Germany)". Symptom assessment and patient-reported outcome measure questionnaires were analyzed at 3 and 12 months (3/12MFU) after diagnosis. Scores indicative of PCS severity were compared and correlated to demographic and clinical characteristics as well as quality of life (QoL, EQ-5D-5L). Results Six hundred three patients (mean 54.0 years, 60.6% male, 82.0% hospitalized) were included. Among those, 35.7% (215) had no and 64.3% (388) had mild, moderate, or severe PCS. PCS severity groups differed considering sex and pre-existing respiratory diseases. 3MFU PCS worsened with clinical severity of acute infection (p = .011), and number of comorbidities (p = .004). PCS severity was associated with poor QoL at the 3MFU and 12MFU (p Conclusion The PCS score correlated with patients' QoL and demonstrated to be instructive for clinical characterization and stratification across health care settings. Further studies should critically address the high prevalence, clinical relevance, and the role of comorbidities. Trail registration number The cohort is registered at www.clinicaltrials.gov under NCT04768998.
| DOI: | 10.1007/s15010-024-02226-9 |
Abstract:
Abstract Purpose The objective examination of the Post-COVID syndrome (PCS) remains difficult due to heterogeneous definitions and clinical phenotypes. The aim of the study was to verify the functionality and correlates of a recently developed PCS score. Methods The PCS score was applied to the prospective, multi-center cross-sectoral cohort (in- and outpatients with SARS-CoV-2 infection) of the "National Pandemic Cohort Network (NAPKON, Germany)". Symptom assessment and patient-reported outcome measure questionnaires were analyzed at 3 and 12 months (3/12MFU) after diagnosis. Scores indicative of PCS severity were compared and correlated to demographic and clinical characteristics as well as quality of life (QoL, EQ-5D-5L). Results Six hundred three patients (mean 54.0 years, 60.6% male, 82.0% hospitalized) were included. Among those, 35.7% (215) had no and 64.3% (388) had mild, moderate, or severe PCS. PCS severity groups differed considering sex and pre-existing respiratory diseases. 3MFU PCS worsened with clinical severity of acute infection (p = .011), and number of comorbidities (p = .004). PCS severity was associated with poor QoL at the 3MFU and 12MFU (p Conclusion The PCS score correlated with patients' QoL and demonstrated to be instructive for clinical characterization and stratification across health care settings. Further studies should critically address the high prevalence, clinical relevance, and the role of comorbidities. Trail registration number The cohort is registered at www.clinicaltrials.gov under NCT04768998.
[en]
M. Weiß,
J. Gutzeit,
K. S. Appel,
T. Bahmer,
M. Beutel,
J. Deckert,
J. Fricke,
S. Hanß,
N. Hettich-Damm,
P. U. Heuschmann,
A. Horn,
K. Jauch-Chara,
M. Kohls,
L. Krist,
B. Lorenz-Depiereux,
C. Otte,
D. Pape,
J. Reese,
S. Schreiber,
S. Störk,
J. J. Vehreschild and
G. Hein,
"Depression and fatigue six months post-COVID-19 disease are
associated with overlapping symptom constellations: A
prospective, multi-center, population-based cohort study",
J. Affect. Disord.,
vol. 352,
pp. 296—305,
Mai
2024.
Elsevier BV.
| DOI: | 10.1016/j.jad.2024.02.041 |
[de]
S. Windeck,
K. Allgoewer,
S. Stillfried,
L. Triefenbach,
U. Nienaber,
R. D. Bülow,
R. Röhrig,
B. Ondruschka,
P. Boor and
NATON,
"Entwicklung und Fortschritte des Nationalen Obduktionsnetzwerks (NATON)",
Die Pathologie,
Mä.
2024.
Abstract:
Obduktionen gelten seit langem als der Goldstandard für die Qualitätssicherung in der Medizin. Die COVID-19-Pandemie hat ihr Potenzial für das Verständnis der Pathophysiologie, Therapie und Krankheitsbewältigung wieder in den Fokus gerückt. Im April 2020 wurde das Deutsche Register für COVID-19-Obduktionen (DeRegCOVID) eingerichtet, gefolgt vom Konsortium DEFEAT PANDEMIcs (2020–2021), das sich zum Nationalen Obduktionsnetzwerk (NATON) entwickelte.
| DOI: | 10.1007/s00292-024-01307-8 |
| Datei: | https://doi.org/10.1007/s00292-024-01307-8 |
Abstract:
Obduktionen gelten seit langem als der Goldstandard für die Qualitätssicherung in der Medizin. Die COVID-19-Pandemie hat ihr Potenzial für das Verständnis der Pathophysiologie, Therapie und Krankheitsbewältigung wieder in den Fokus gerückt. Im April 2020 wurde das Deutsche Register für COVID-19-Obduktionen (DeRegCOVID) eingerichtet, gefolgt vom Konsortium DEFEAT PANDEMIcs (2020–2021), das sich zum Nationalen Obduktionsnetzwerk (NATON) entwickelte.
[eng]
L. Zhou,
M. T. Pereiro,
Y. Li,
M. Derigs,
C. Kuenne,
T. Hielscher,
W. Huang,
B. Kränzlin,
G. Tian,
K. Kobayashi,
G. N. Lu,
K. Roedl,
C. Schmidt,
S. Günther,
M. Looso,
J. Huber,
Y. Xu,
T. Wiech,
J. Sperhake,
D. Wichmann,
H. Gröne and
T. Worzfeld,
"Glucocorticoids induce a maladaptive epithelial stress response to aggravate acute kidney injury",
Science Translational Medicine,
vol. 16,
no. 767,
pp. eadk5005,
Okt.
2024.
Abstract:
Acute kidney injury (AKI) is a frequent and challenging clinical condition associated with high morbidity and mortality and represents a common complication in critically ill patients with COVID-19. In AKI, renal tubular epithelial cells (TECs) are a primary site of damage, and recovery from AKI depends on TEC plasticity. However, the molecular mechanisms underlying adaptation and maladaptation of TECs in AKI remain largely unclear. Here, our study of an autopsy cohort of patients with COVID-19 provided evidence that injury of TECs by myoglobin, released as a consequence of rhabdomyolysis, is a major pathophysiological mechanism for AKI in severe COVID-19. Analyses of human kidney biopsies, mouse models of myoglobinuric and gentamicin-induced AKI, and mouse kidney tubuloids showed that TEC injury resulted in activation of the glucocorticoid receptor by endogenous glucocorticoids, which aggravated tubular damage. The detrimental effect of endogenous glucocorticoids on injured TECs was exacerbated by the administration of a widely clinically used synthetic glucocorticoid, dexamethasone, as indicated by experiments in mouse models of myoglobinuric- and folic acid-induced AKI, human and mouse kidney tubuloids, and human kidney slice cultures. Mechanistically, studies in mouse models of AKI, mouse tubuloids, and human kidney slice cultures demonstrated that glucocorticoid receptor signaling in injured TECs orchestrated a maladaptive transcriptional program to hinder DNA repair, amplify injury-induced DNA double-strand break formation, and dampen mTOR activity and mitochondrial bioenergetics. This study identifies glucocorticoid receptor activation as a mechanism of epithelial maladaptation, which is functionally important for AKI.
| DOI: | 10.1126/scitranslmed.adk5005 |
Abstract:
Acute kidney injury (AKI) is a frequent and challenging clinical condition associated with high morbidity and mortality and represents a common complication in critically ill patients with COVID-19. In AKI, renal tubular epithelial cells (TECs) are a primary site of damage, and recovery from AKI depends on TEC plasticity. However, the molecular mechanisms underlying adaptation and maladaptation of TECs in AKI remain largely unclear. Here, our study of an autopsy cohort of patients with COVID-19 provided evidence that injury of TECs by myoglobin, released as a consequence of rhabdomyolysis, is a major pathophysiological mechanism for AKI in severe COVID-19. Analyses of human kidney biopsies, mouse models of myoglobinuric and gentamicin-induced AKI, and mouse kidney tubuloids showed that TEC injury resulted in activation of the glucocorticoid receptor by endogenous glucocorticoids, which aggravated tubular damage. The detrimental effect of endogenous glucocorticoids on injured TECs was exacerbated by the administration of a widely clinically used synthetic glucocorticoid, dexamethasone, as indicated by experiments in mouse models of myoglobinuric- and folic acid-induced AKI, human and mouse kidney tubuloids, and human kidney slice cultures. Mechanistically, studies in mouse models of AKI, mouse tubuloids, and human kidney slice cultures demonstrated that glucocorticoid receptor signaling in injured TECs orchestrated a maladaptive transcriptional program to hinder DNA repair, amplify injury-induced DNA double-strand break formation, and dampen mTOR activity and mitochondrial bioenergetics. This study identifies glucocorticoid receptor activation as a mechanism of epithelial maladaptation, which is functionally important for AKI.
[eng]
M. Schwabenland,
D. Hasavci,
S. Frase,
K. Wolf,
N. Deigendesch,
J. M. Buescher,
K. D. Mertz,
B. Ondruschka,
H. Altmeppen,
J. Matschke,
M. Glatzel,
S. Frank,
R. Thimme,
J. Beck,
J. A. Hosp,
T. Blank,
B. Bengsch and
M. Prinz,
"High throughput spatial immune mapping reveals an innate immune scar in post-COVID-19 brains",
Acta Neuropathologica,
vol. 148,
no. 1,
pp. 11,
Jul.
2024.
Abstract:
The underlying pathogenesis of neurological sequelae in post-COVID-19 patients remains unclear. Here, we used multidimensional spatial immune phenotyping and machine learning methods on brains from initial COVID-19 survivors to identify the biological correlate associated with previous SARS-CoV-2 challenge. Compared to healthy controls, individuals with post-COVID-19 revealed a high percentage of TMEM119+P2RY12+CD68+Iba1+HLA-DR+CD11c+SCAMP2+ microglia assembled in prototypical cellular nodules. In contrast to acute SARS-CoV-2 cases, the frequency of CD8+ parenchymal T cells was reduced, suggesting an immune shift toward innate immune activation that may contribute to neurological alterations in post-COVID-19 patients.
| DOI: | 10.1007/s00401-024-02770-6 |
Abstract:
The underlying pathogenesis of neurological sequelae in post-COVID-19 patients remains unclear. Here, we used multidimensional spatial immune phenotyping and machine learning methods on brains from initial COVID-19 survivors to identify the biological correlate associated with previous SARS-CoV-2 challenge. Compared to healthy controls, individuals with post-COVID-19 revealed a high percentage of TMEM119+P2RY12+CD68+Iba1+HLA-DR+CD11c+SCAMP2+ microglia assembled in prototypical cellular nodules. In contrast to acute SARS-CoV-2 cases, the frequency of CD8+ parenchymal T cells was reduced, suggesting an immune shift toward innate immune activation that may contribute to neurological alterations in post-COVID-19 patients.
[en]
E. Orban,
L. Y. Li,
M. Gilbert,
A. Napp,
A. Kaman,
S. Topf,
M. Boecker,
J. Devine,
F. Reiß,
F. Wendel,
C. Jung-Sievers,
V. S. Ernst,
M. Franze,
E. Möhler,
E. Breitinger,
S. Bender and
U. Ravens-Sieberer,
"Mental health and quality of life in children and adolescents
during the COVID-19 pandemic: a systematic review of
longitudinal studies",
Front Public Health,
vol. 11,
pp. 1275917,
Jan.
2024.
Abstract:
BACKGROUND: The COVID-19 pandemic has significantly impacted the mental health of children and families, i.e., due to measures like social distancing and remote schooling. While previous research has shown negative effects on mental health and health-related quality of life (HRQoL), most studies have focused on pre-post comparisons in the early pandemic stages. This systematic review aims to examine longitudinal studies to understand the long-term impacts of the pandemic on children and adolescents. METHODS: This systematic review adhered to the PRISMA guidelines and was preregistered in the international prospective register of systematic reviews (Record ID: CRD42022336930). We systematically searched PubMed/MEDLINE, Web of Science, PsycINFO, PSYNDEX, and the WHO-COVID-19 database and included studies published up to August 30, 2022. Based on pre-defined eligibility criteria, longitudinal and prospective studies that assessed the mental health or quality of life of children or adolescents (0-19 years) in the general population over a longer time span (at two or more measurement points) during the COVID-19 pandemic were included in the review. The methodological quality of the included studies was assessed using an adapted version of the Effective Public Health Practice Project (EPHPP) checklist. Narrative data synthesis was used to summarize the findings. RESULTS: A total of 5,099 results were obtained from literature searches, with 4,935 excluded during title/abstract screening. After reviewing 163 full-text articles, 24 publications were included in the review. Sample sizes ranged between n = 86 and n = 34,038. The length of the investigated time periods and the number of assessment points, as well as outcomes, varied. The majority of studies were of moderate methodological quality. Mental health outcomes were more frequently studied compared to measures of HRQoL. The findings from these studies mostly suggest that children and adolescents experienced heightened mental health problems, specifically internalizing symptoms like anxiety and depression. Further, there was a decline in their overall HRQoL over the course of the COVID-19 pandemic that did not necessarily subside when lockdowns ended. CONCLUSION: It is crucial to continue monitoring the mental health and well-being of children and adolescents following the pandemic to identify groups at risks and plan interventions. This should ideally be conducted by large systematic studies, using validated instruments, and encompassing representative samples to obtain reliable and comprehensive insights with the aim of improving youth mental health care.
| DOI: | https://doi.org/10.3389/fpubh.2023.1275917 |
Abstract:
BACKGROUND: The COVID-19 pandemic has significantly impacted the mental health of children and families, i.e., due to measures like social distancing and remote schooling. While previous research has shown negative effects on mental health and health-related quality of life (HRQoL), most studies have focused on pre-post comparisons in the early pandemic stages. This systematic review aims to examine longitudinal studies to understand the long-term impacts of the pandemic on children and adolescents. METHODS: This systematic review adhered to the PRISMA guidelines and was preregistered in the international prospective register of systematic reviews (Record ID: CRD42022336930). We systematically searched PubMed/MEDLINE, Web of Science, PsycINFO, PSYNDEX, and the WHO-COVID-19 database and included studies published up to August 30, 2022. Based on pre-defined eligibility criteria, longitudinal and prospective studies that assessed the mental health or quality of life of children or adolescents (0-19 years) in the general population over a longer time span (at two or more measurement points) during the COVID-19 pandemic were included in the review. The methodological quality of the included studies was assessed using an adapted version of the Effective Public Health Practice Project (EPHPP) checklist. Narrative data synthesis was used to summarize the findings. RESULTS: A total of 5,099 results were obtained from literature searches, with 4,935 excluded during title/abstract screening. After reviewing 163 full-text articles, 24 publications were included in the review. Sample sizes ranged between n = 86 and n = 34,038. The length of the investigated time periods and the number of assessment points, as well as outcomes, varied. The majority of studies were of moderate methodological quality. Mental health outcomes were more frequently studied compared to measures of HRQoL. The findings from these studies mostly suggest that children and adolescents experienced heightened mental health problems, specifically internalizing symptoms like anxiety and depression. Further, there was a decline in their overall HRQoL over the course of the COVID-19 pandemic that did not necessarily subside when lockdowns ended. CONCLUSION: It is crucial to continue monitoring the mental health and well-being of children and adolescents following the pandemic to identify groups at risks and plan interventions. This should ideally be conducted by large systematic studies, using validated instruments, and encompassing representative samples to obtain reliable and comprehensive insights with the aim of improving youth mental health care.
J. Lücke,
M. Böttcher,
M. Nawrocki,
N. Meins,
J. Schnell,
F. Heinrich,
F. Bertram,
M. Sabihi,
P. Seeger,
M. Pfaff,
S. Notz,
T. Blankenburg,
T. Zhang,
J. Kempski,
M. Reeh,
S. Wolter,
O. Mann,
M. Lütgehetmann,
T. Hackert,
J. R. Izbicki,
A. Duprée,
S. Huber,
B. Ondruschka and
A. D. Giannou,
"Obesity and diabetes mellitus are associated with SARS-CoV-2 outcomes without influencing signature genes of extrapulmonary immune compartments at the RNA level",
Heliyon,
vol. 10,
no. 2,
pp. e24508,
2024.
Abstract:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is responsible for eliciting Coronavirus disease 2019 (COVID-19) still challenges healthcare services worldwide. While many patients only suffer from mild symptoms, patients with some pre-existing medical conditions are at a higher risk for a detrimental course of disease. However, the underlying mechanisms determining disease course are only partially understood. One key factor influencing disease severity is described to be immune-mediated. In this report, we describe a post-mortem analysis of 45 individuals who died from SARS-CoV-2 infection. We could show that although sociodemographic factors and premedical conditions such as obesity and diabetes mellitus reduced survival time in our cohort, they were not associated with changes in the expression of immune-related signature genes at the RNA level in the blood, the gut, or the liver between these different groups. Our data indicate that obesity and diabetes mellitus influence SARS-CoV-2-related mortality, without influencing the extrapulmonary gene expression of immunity-related signature genes at the RNA level.
| DOI: | https://doi.org/10.1016/j.heliyon.2024.e24508 |
| Datei: | https://www.sciencedirect.com/science/article/pii/S2405844024005395 |
Abstract:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is responsible for eliciting Coronavirus disease 2019 (COVID-19) still challenges healthcare services worldwide. While many patients only suffer from mild symptoms, patients with some pre-existing medical conditions are at a higher risk for a detrimental course of disease. However, the underlying mechanisms determining disease course are only partially understood. One key factor influencing disease severity is described to be immune-mediated. In this report, we describe a post-mortem analysis of 45 individuals who died from SARS-CoV-2 infection. We could show that although sociodemographic factors and premedical conditions such as obesity and diabetes mellitus reduced survival time in our cohort, they were not associated with changes in the expression of immune-related signature genes at the RNA level in the blood, the gut, or the liver between these different groups. Our data indicate that obesity and diabetes mellitus influence SARS-CoV-2-related mortality, without influencing the extrapulmonary gene expression of immunity-related signature genes at the RNA level.
[English]
Z. Rong,
H. Mai,
G. Ebert,
S. Kapoor,
V. G. Puelles,
J. Czogalla,
S. Hu,
J. Su,
D. Prtvar,
I. Singh,
J. Schädler,
C. Delbridge,
H. Steinke,
H. Frenzel,
K. Schmidt,
C. Braun,
G. Bruch,
V. Ruf,
M. Ali,
K. Sühs,
M. Nemati,
F. Hopfner,
S. Ulukaya,
D. Jeridi,
D. Mistretta,
O. S. Caliskan,
J. M. Wettengel,
F. Cherif,
Z. I. Kolabas,
M. Molbay,
I. Horvath,
S. Zhao,
N. Krahmer,
A. Ö. Yildirim,
S. Ussar,
J. Herms,
T. B. Huber,
S. Tahirovic,
S. M. Schwarzmaier,
N. Plesnila,
G. Höglinger,
B. Ondruschka,
I. Bechmann,
U. Protzer,
M. Elsner,
H. S. Bhatia,
F. Hellal and
A. Erturk,
"Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19",
Cell Host & Microbe,
Nov.
2024.
| DOI: | 10.1016/j.chom.2024.11.007 |
| Datei: | https://www.cell.com/cell-host-microbe/abstract/S1931-3128(24)00438-4 |
[en]
J. Schädler,
M. Lütgehetmann,
A. S. Schröder,
C. Edler,
K. Püschel,
B. Ondruschka and
A. Fitzek,
"Pilot study in Hamburg on the prevalence of SARS-CoV-2 infections and pandemic survey in the German funeral industry",
Forensic Science, Medicine and Pathology,
vol. 20,
pp. 500—507,
2024.
Abstract:
Funeral home and crematorium workers are an important occupational group in the corona crisis. The occupational setting led to concerns about an increased risk of infection with SARS-CoV-2. The seroprevalence in this occupational group is unclear. A questionnaire-based retrospective survey of funeral home and crematorium staff was conducted in December 2020. A second survey of funeral and crematorium staff was conducted 6 months later, in June 2021, to determine changes in pandemic management. Seroprevalence or vaccination status for SARS-CoV-2 was determined at these two time points. In December 2020, a seroprevalence of 2.3% (n = 1/44) was detected in funeral home and crematorium workers. In June 2021, one additional participant tested positive for the SARS-CoV-2 nucleocapsid. Of the participants, 48.5% (n = 16) were vaccinated at this time. The risk of SARS-CoV-2 infection for funeral home and crematorium workers is more similar to that of the general population in Hamburg, Germany. We found no evidence of an increased risk of infection at these two time points in our cohort. Further education on communicable diseases or appropriate protective measures in this occupational group for other infectious diseases would be useful in the future.
| DOI: | 10.1007/s12024-023-00661-y |
| Datei: | https://doi.org/10.1007/s12024-023-00661-y |
Abstract:
Funeral home and crematorium workers are an important occupational group in the corona crisis. The occupational setting led to concerns about an increased risk of infection with SARS-CoV-2. The seroprevalence in this occupational group is unclear. A questionnaire-based retrospective survey of funeral home and crematorium staff was conducted in December 2020. A second survey of funeral and crematorium staff was conducted 6 months later, in June 2021, to determine changes in pandemic management. Seroprevalence or vaccination status for SARS-CoV-2 was determined at these two time points. In December 2020, a seroprevalence of 2.3% (n = 1/44) was detected in funeral home and crematorium workers. In June 2021, one additional participant tested positive for the SARS-CoV-2 nucleocapsid. Of the participants, 48.5% (n = 16) were vaccinated at this time. The risk of SARS-CoV-2 infection for funeral home and crematorium workers is more similar to that of the general population in Hamburg, Germany. We found no evidence of an increased risk of infection at these two time points in our cohort. Further education on communicable diseases or appropriate protective measures in this occupational group for other infectious diseases would be useful in the future.
[en]
F. Gaertner,
H. Ishikawa-Ankerhold,
S. Stutte,
W. Fu,
J. Weitz,
A. Dueck,
B. Nelakuditi,
V. Fumagalli,
D. Van Den Heuvel,
L. Belz,
G. Sobirova,
Z. Zhang,
A. Titova,
A. M. Navarro,
K. Pekayvaz,
M. Lorenz,
L. Von Baumgarten,
J. Kranich,
T. Straub,
B. Popper,
V. Zheden,
W. A. Kaufmann,
C. Guo,
G. Piontek,
S. Von Stillfried,
P. Boor,
M. Colonna,
S. Clauß,
C. Schulz,
T. Brocker,
B. Walzog,
C. Scheiermann,
W. C. Aird,
C. Nerlov,
K. Stark,
T. Petzold,
S. Engelhardt,
M. Sixt,
R. Hauschild,
M. Rudelius,
R. A. J. Oostendorp,
M. Iannacone,
M. Heinig and
S. Massberg,
"Plasmacytoid dendritic cells control homeostasis of megakaryopoiesis",
Nature,
vol. 631,
no. 8021,
pp. 645—653,
Jul.
2024.
Abstract:
Abstract Platelet homeostasis is essential for vascular integrity and immune defence 1,2 . Although the process of platelet formation by fragmenting megakaryocytes (MKs; thrombopoiesis) has been extensively studied, the cellular and molecular mechanisms required to constantly replenish the pool of MKs by their progenitor cells (megakaryopoiesis) remains unclear 3,4 . Here we use intravital imaging to track the cellular dynamics of megakaryopoiesis over days. We identify plasmacytoid dendritic cells (pDCs) as homeostatic sensors that monitor the bone marrow for apoptotic MKs and deliver IFNα to the MK niche triggering local on-demand proliferation and maturation of MK progenitors. This pDC-dependent feedback loop is crucial for MK and platelet homeostasis at steady state and under stress. pDCs are best known for their ability to function as vigilant detectors of viral infection 5 . We show that virus-induced activation of pDCs interferes with their function as homeostatic sensors of megakaryopoiesis. Consequently, activation of pDCs by SARS-CoV-2 leads to excessive megakaryopoiesis. Together, we identify a pDC-dependent homeostatic circuit that involves innate immune sensing and demand-adapted release of inflammatory mediators to maintain homeostasis of the megakaryocytic lineage.
| DOI: | 10.1038/s41586-024-07671-y |
| Datei: | https://www.nature.com/articles/s41586-024-07671-y |
Abstract:
Abstract Platelet homeostasis is essential for vascular integrity and immune defence 1,2 . Although the process of platelet formation by fragmenting megakaryocytes (MKs; thrombopoiesis) has been extensively studied, the cellular and molecular mechanisms required to constantly replenish the pool of MKs by their progenitor cells (megakaryopoiesis) remains unclear 3,4 . Here we use intravital imaging to track the cellular dynamics of megakaryopoiesis over days. We identify plasmacytoid dendritic cells (pDCs) as homeostatic sensors that monitor the bone marrow for apoptotic MKs and deliver IFNα to the MK niche triggering local on-demand proliferation and maturation of MK progenitors. This pDC-dependent feedback loop is crucial for MK and platelet homeostasis at steady state and under stress. pDCs are best known for their ability to function as vigilant detectors of viral infection 5 . We show that virus-induced activation of pDCs interferes with their function as homeostatic sensors of megakaryopoiesis. Consequently, activation of pDCs by SARS-CoV-2 leads to excessive megakaryopoiesis. Together, we identify a pDC-dependent homeostatic circuit that involves innate immune sensing and demand-adapted release of inflammatory mediators to maintain homeostasis of the megakaryocytic lineage.
[en]
T. Lahmer,
G. Weirich,
S. Porubsky,
S. Rasch,
F. A. Kammerstetter,
C. Schustetter,
P. Schüffler,
J. Erber,
M. Dibos,
C. Delbridge,
P. H. Kuhn,
S. Jeske,
M. Steinhardt,
A. Chaker,
M. Heim,
U. Heemann,
R. M. Schmid,
W. Weichert,
K. F. Stock and
J. Slotta-Huspenina,
"Postmortem Minimally Invasive Autopsy in Critically Ill COVID-19 Patients at the Bedside: A Proof-of-Concept Study at the ICU",
Diagnostics,
vol. 14,
no. 3,
pp. 294,
Jan.
2024.
Abstract:
Background: Economic restrictions and workforce cuts have continually challenged conventional autopsies. Recently, the COVID-19 pandemic has added tissue quality and safety requirements to the investigation of this disease, thereby launching efforts to upgrade autopsy strategies. Methods: In this proof-of-concept study, we performed bedside ultrasound-guided minimally invasive autopsy (US-MIA) in the ICU of critically ill COVID-19 patients using a structured protocol to obtain non-autolyzed tissue. Biopsies were assessed for their quality (vitality) and length of biopsy (mm) and for diagnosis. The efficiency of the procedure was monitored in five cases by recording the time of each step and safety issues by swabbing personal protective equipment and devices for viral contamination. Findings: Ultrasound examination and tissue procurement required a mean time period of 13 min and 54 min, respectively. A total of 318 multiorgan biopsies were obtained from five patients. Quality and vitality standards were fulfilled, which not only allowed for specific histopathological diagnosis but also the reliable detection of SARS-CoV-2 virions in unexpected organs using electronic microscopy and RNA-expressing techniques. Interpretation: Bedside multidisciplinary US-MIA allows for the fast and efficient acquisition of autolytic-free tissue and offers unappreciated potential to overcome the limitations of research in postmortem studies.
| DOI: | 10.3390/diagnostics14030294 |
| Datei: | https://www.mdpi.com/2075-4418/14/3/294 |
Abstract:
Background: Economic restrictions and workforce cuts have continually challenged conventional autopsies. Recently, the COVID-19 pandemic has added tissue quality and safety requirements to the investigation of this disease, thereby launching efforts to upgrade autopsy strategies. Methods: In this proof-of-concept study, we performed bedside ultrasound-guided minimally invasive autopsy (US-MIA) in the ICU of critically ill COVID-19 patients using a structured protocol to obtain non-autolyzed tissue. Biopsies were assessed for their quality (vitality) and length of biopsy (mm) and for diagnosis. The efficiency of the procedure was monitored in five cases by recording the time of each step and safety issues by swabbing personal protective equipment and devices for viral contamination. Findings: Ultrasound examination and tissue procurement required a mean time period of 13 min and 54 min, respectively. A total of 318 multiorgan biopsies were obtained from five patients. Quality and vitality standards were fulfilled, which not only allowed for specific histopathological diagnosis but also the reliable detection of SARS-CoV-2 virions in unexpected organs using electronic microscopy and RNA-expressing techniques. Interpretation: Bedside multidisciplinary US-MIA allows for the fast and efficient acquisition of autolytic-free tissue and offers unappreciated potential to overcome the limitations of research in postmortem studies.
F. Brinkmann,
A. Friedrichs,
G. M. Behrens,
P. Behrens,
R. Berner,
A. Caliebe,
C. M. Denkinger,
K. Giesbrecht,
A. Gussew,
A. T. Hoffmann,
L. Hojenski,
O. Hovardovska,
A. Dopfer-Jablonka,
A. J. Kaasch,
R. Kobbe,
M. Kraus,
A. Lindner,
C. Maier,
L. Mitrov,
M. Nauck,
S. N. Miranda,
M. Scherer,
Y. Schmiedel,
D. Stahl,
N. Timmesfeld,
N. Toepfner,
J. Vehreschild,
W. A. Wohlgemuth,
A. Petersmann and
M. J. G. T. Vehreschild,
"Prevalence of infectious diseases, immunity to vaccine-preventable diseases and chronic medical conditions among Ukrainian refugees in Germany – a cross sectional study from the German Network University Medicine (NUM)",
Journal of Infection and Public Health,
vol. Online ahead of print,
2024.
Abstract:
Background Vulnerability to infectious diseases in refugees is dependent on country of origin, flight routes, and conditions. Information on specific medical needs of different groups of refugees is lacking. We assessed the prevalence of infectious diseases, immunity to vaccine-preventable diseases, and chronic medical conditions in children, adolescents, and adult refugees from Ukraine who arrived in Germany in 2022. Methods Using different media, we recruited Ukrainian refugees at 13 sites between 9-12/2022. An antigen test for acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, serologies for a range of vaccine-preventable diseases, as well as interferon gamma release assays (IGRAs) for tuberculosis (TB), and SARS-CoV-2 were performed. We assessed personal and family history of chronic medical conditions, infectious diseases, vaccination status, and conditions during migration. Results Overall, 1,793 refugees (1,401 adults and 392 children/adolescents) were included. Most participants were females (n=1,307; 72·3%) and from Eastern or Southern Ukraine. TB IGRA was positive in 13% (n=184) of the adults and in 2% (n=7) of the children. Serology-based immunological response was insufficient in approximately 21% (360/1793) of the participants for measles, 32% (572/1793) for diphtheria, and 74% (1,289/1,793) for hepatitis B. Conclusions We show evidence of low serological response to vaccine-preventable infections and increased LTBI prevalence in Ukrainian refugees. These findings should be integrated into guidelines for screening and treatment of infectious diseases in migrants and refugees in Germany and Europe. Furthermore, low immunity for vaccine-preventable diseases in Ukrainians independent of their refugee status, calls for tailor-made communication efforts.
| DOI: | https://doi.org/10.1016/j.jiph.2024.02.003 |
| Datei: | https://www.sciencedirect.com/science/article/pii/S1876034124000297 |
Abstract:
Background Vulnerability to infectious diseases in refugees is dependent on country of origin, flight routes, and conditions. Information on specific medical needs of different groups of refugees is lacking. We assessed the prevalence of infectious diseases, immunity to vaccine-preventable diseases, and chronic medical conditions in children, adolescents, and adult refugees from Ukraine who arrived in Germany in 2022. Methods Using different media, we recruited Ukrainian refugees at 13 sites between 9-12/2022. An antigen test for acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, serologies for a range of vaccine-preventable diseases, as well as interferon gamma release assays (IGRAs) for tuberculosis (TB), and SARS-CoV-2 were performed. We assessed personal and family history of chronic medical conditions, infectious diseases, vaccination status, and conditions during migration. Results Overall, 1,793 refugees (1,401 adults and 392 children/adolescents) were included. Most participants were females (n=1,307; 72·3%) and from Eastern or Southern Ukraine. TB IGRA was positive in 13% (n=184) of the adults and in 2% (n=7) of the children. Serology-based immunological response was insufficient in approximately 21% (360/1793) of the participants for measles, 32% (572/1793) for diphtheria, and 74% (1,289/1,793) for hepatitis B. Conclusions We show evidence of low serological response to vaccine-preventable infections and increased LTBI prevalence in Ukrainian refugees. These findings should be integrated into guidelines for screening and treatment of infectious diseases in migrants and refugees in Germany and Europe. Furthermore, low immunity for vaccine-preventable diseases in Ukrainians independent of their refugee status, calls for tailor-made communication efforts.
[en]
J. Radke,
J. Meinhardt,
T. Aschman,
R. L. Chua,
V. Farztdinov,
S. Lukassen,
F. W. Ten,
E. Friebel,
N. Ishaque,
J. Franz,
V. H. Huhle,
R. Mothes,
K. Peters,
C. Thomas,
S. Schneeberger,
E. Schumann,
L. Kawelke,
J. Jünger,
V. Horst,
S. Streit,
R. Manitius,
P. Körtvélyessy,
S. Vielhaber,
D. Reinhold,
A. E. Hauser,
A. Osterloh,
P. Enghard,
J. Ihlow,
S. Elezkurtaj,
D. Horst,
F. Kurth,
M. A. Müller,
N. C. Gassen,
J. Melchert,
K. Jechow,
B. Timmermann,
C. Fernandez-Zapata,
C. Böttcher,
W. Stenzel,
E. Krüger,
M. Landthaler,
E. Wyler,
V. Corman,
C. Stadelmann,
M. Ralser,
R. Eils,
F. L. Heppner,
M. Mülleder,
C. Conrad and
H. Radbruch,
"Proteomic and transcriptomic profiling of brainstem, cerebellum
and olfactory tissues in early- and late-phase COVID-19",
Nat Neurosci. Online ahead of print,
Feb.
2024.
| DOI: | https://doi.org/10.1038/s41593-024-01573-y |
M. Misailovski,
D. Koller,
S. Blaschke,
M. Berens,
A. M. Köster,
R. Strobl,
R. Berner,
P. Boor,
M. Eisenmann,
S. Stillfried,
D. Krefting,
M. Krone,
J. Liese,
P. Meybohm,
G. Ulrich- Merzenich,
S. Zenker,
S. Scheithauer and
E. Grill,
"Refining the hospitalization rate: A mixed methods approach to differentiate primary COVID-19 from incidental cases",
Infection Prevention in Practice,
vol. 6,
no. 3,
pp. 100371,
Sep.
2024.
Abstract:
Purpose Until now, the Hospitalization Rate (HR) served as an indicator (among others) for the COVID-19 associated healthcare burden. To ensure that the HR accomplishes its full potential, hospitalizations caused by COVID-19 (primary cases) and hospitalizations of patients with incidental positive SARS-CoV-2 test results (incidental cases) must be differentiated. The aim of this study was to synthesize the existing evidence on differentiation criteria between hospitalizations of primary cases and incidental cases. Methods An online survey of the members of the German Network University Medicine (NUM) was conducted. Additionally, senior clinicians with expertise in COVID-19 care were invited for qualitative, semi-structured interviews. Furthermore, a rapid literature review was undertaken on publications between 03/2020 and 12/2022. Results In the online survey (n=30, response rate 56%), pneumonia and acute upper respiratory tract infections were the most indicative diagnoses for a primary case. In contrast, malignant neoplasms and acute myocardial infarctions were most likely to be associated with incidental cases. According to the experts (n=6), the diagnosis, ward, and type of admission (emergency or elective), low oxygen saturation, need for supplemental oxygen, and initiation of COVID-19 therapy point to a primary case. The literature review found that respiratory syndromes and symptoms, oxygen support, and elevated levels of inflammatory markers were associated with primary cases. Conclusion There are parameters for the differentiation of primary from incidental cases to improve the objective of the HR. Ultimately, an updated HR has the potential to serve as a more accurate indicator of the COVID-19 associated healthcare burden.
| DOI: | 10.1016/j.infpip.2024.100371 |
| Datei: | https://www.sciencedirect.com/science/article/pii/S2590088924000350 |
Abstract:
Purpose Until now, the Hospitalization Rate (HR) served as an indicator (among others) for the COVID-19 associated healthcare burden. To ensure that the HR accomplishes its full potential, hospitalizations caused by COVID-19 (primary cases) and hospitalizations of patients with incidental positive SARS-CoV-2 test results (incidental cases) must be differentiated. The aim of this study was to synthesize the existing evidence on differentiation criteria between hospitalizations of primary cases and incidental cases. Methods An online survey of the members of the German Network University Medicine (NUM) was conducted. Additionally, senior clinicians with expertise in COVID-19 care were invited for qualitative, semi-structured interviews. Furthermore, a rapid literature review was undertaken on publications between 03/2020 and 12/2022. Results In the online survey (n=30, response rate 56%), pneumonia and acute upper respiratory tract infections were the most indicative diagnoses for a primary case. In contrast, malignant neoplasms and acute myocardial infarctions were most likely to be associated with incidental cases. According to the experts (n=6), the diagnosis, ward, and type of admission (emergency or elective), low oxygen saturation, need for supplemental oxygen, and initiation of COVID-19 therapy point to a primary case. The literature review found that respiratory syndromes and symptoms, oxygen support, and elevated levels of inflammatory markers were associated with primary cases. Conclusion There are parameters for the differentiation of primary from incidental cases to improve the objective of the HR. Ultimately, an updated HR has the potential to serve as a more accurate indicator of the COVID-19 associated healthcare burden.
L. Zhang,
A. Kempf,
I. Nehlmeier,
A. Cossmann,
A. Richter,
N. Bdeir,
L. Graichen,
A. Moldenhauer,
A. Dopfer-Jablonka,
M. V. Stankov,
E. Simon-Loriere,
S. R. Schulz,
H. Jäck,
L. Cičin-Šain,
G. M. N. Behrens,
C. Drosten,
M. Hoffmann and
S. Pöhlmann,
"SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency",
Cell,
2024.
Abstract:
BA.2.86, a recently identified descendant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 sublineage, contains $\sim$35 mutations in the spike (S)~protein and spreads in multiple countries. Here, we investigated whether the virus exhibits altered biological traits, focusing on S protein-driven viral entry. Employing pseudotyped particles, we show that BA.2.86, unlike other Omicron sublineages, enters Calu-3 lung cells with high efficiency and in a serine- but not cysteine-protease-dependent manner. Robust lung cell infection was confirmed with authentic BA.2.86, but the virus exhibited low specific infectivity. Further, BA.2.86 was highly resistant against all therapeutic antibodies tested, efficiently evading neutralization by antibodies induced by non-adapted vaccines. In contrast, BA.2.86 and the currently circulating EG.5.1 sublineage were appreciably neutralized by antibodies induced by the XBB.1.5-adapted vaccine. Collectively, BA.2.86 has regained a trait characteristic of early SARS-CoV-2 lineages, robust lung cell entry, and evades neutralizing antibodies. However, BA.2.86 exhibits low specific infectivity, which might limit transmissibility.
| DOI: | 10.1016/j.cell.2023.12.025 |
Abstract:
BA.2.86, a recently identified descendant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 sublineage, contains $\sim$35 mutations in the spike (S)~protein and spreads in multiple countries. Here, we investigated whether the virus exhibits altered biological traits, focusing on S protein-driven viral entry. Employing pseudotyped particles, we show that BA.2.86, unlike other Omicron sublineages, enters Calu-3 lung cells with high efficiency and in a serine- but not cysteine-protease-dependent manner. Robust lung cell infection was confirmed with authentic BA.2.86, but the virus exhibited low specific infectivity. Further, BA.2.86 was highly resistant against all therapeutic antibodies tested, efficiently evading neutralization by antibodies induced by non-adapted vaccines. In contrast, BA.2.86 and the currently circulating EG.5.1 sublineage were appreciably neutralized by antibodies induced by the XBB.1.5-adapted vaccine. Collectively, BA.2.86 has regained a trait characteristic of early SARS-CoV-2 lineages, robust lung cell entry, and evades neutralizing antibodies. However, BA.2.86 exhibits low specific infectivity, which might limit transmissibility.
[en]
M. Mohme,
C. Schultheiß,
A. Piffko,
A. Fitzek,
L. Paschold,
B. Thiele,
K. Püschel,
M. Glatzel,
M. Westphal,
K. Lamszus,
J. Matschke and
M. Binder,
"SARS-CoV-2-associated T-cell infiltration in the central nervous system",
Clinical & Translational Immunology,
vol. 13,
no. 2,
pp. e1487,
Jan.
2024.
Abstract:
In COVID-19 patients, neurological symptoms and complications are increasingly recognised, but their underlying causes remain poorly understood. This study found that SARS-CoV-2-associated T cells we...
| DOI: | 10.1002/cti2.1487 |
| Datei: | https://onlinelibrary.wiley.com/doi/10.1002/cti2.1487 |
Abstract:
In COVID-19 patients, neurological symptoms and complications are increasingly recognised, but their underlying causes remain poorly understood. This study found that SARS-CoV-2-associated T cells we...
B. Lorenz-Depiereux,
T. Bahmer,
S. Ciesek,
M. Mülleder,
S. Mücke,
B. Fösel,
V. Kopfnagel,
C. Dolch,
M. Nauck,
S. Pullamsetti,
M. Looso,
M. Ralser,
C. Schäfer,
M. Schattschneider,
S. Schreiber,
J. Vehreschild,
C. Gieger,
M. Witzenrath,
U. Völker,
G. Anton and
T. Illig,
"Systematic molecular analyses of the NAPKON cohorts - current state and overview, Poster, ESHG 2024 Berlin",
Poster, ESHG 2024 Berlin,
2024.
B. Lorenz-Depiereux,
T. Bahmer,
S. Ciesek,
M. Mülleder,
S. Mücke,
B. Fösel,
V. Kopfnagel,
C. Dolch,
S. Kunze,
M. Nauck,
S. Pullamsetti,
M. Ralser,
C. Schäfer,
M. Schattschneider,
S. Schreiber,
J. J. Vehreschild,
M. Witzenrath,
U. Völker,
T. Illig,
G. Anton,
On Behalf Of The Napkon Study Group,
N. S. Group,
M. Looso and
C. Gieger,
"Systematic molecular analyses of the NAPKON cohorts – an overview",
Präsentation, State of the art speaker T12 – Bioinformatics and –omics and Big data, EBW 2024 Wien,
2024.
B. Lorenz-Depiereux,
T. Bahmer,
S. Ciesek,
M. Mülleder,
S. Mücke,
B. Fösel,
V. Kopfnagel,
C. Dolch,
S. Kunze,
M. Nauck,
S. Pullamsetti,
M. Looso,
M. Ralser,
C. Schäfer,
M. Schattschneider,
S. Schreiber,
J. J. Vehreschild,
C. Gieger,
M. Witzenrath,
U. Völker,
T. Illig,
G. Anton and
On Behalf Of The Napkon Study Group,
"Systematic molecular analyses of the NAPKON cohorts – an overview, Präsentation, State of the art speaker T12 – Bioinformatics and –omics and Big data, EBW 2024 Wien",
Präsentation, State of the art speaker T12 – Bioinformatics and –omics and Big data, EBW 2024 Wien,
2024.
[en]
J. Meinhardt,
S. Streit,
C. Dittmayer,
R. v. Manitius,
H. Radbruch and
F. L. Heppner,
"The neurobiology of SARS-CoV-2 infection",
Nature Reviews Neuroscience,
vol. 25,
no. 1,
pp. 30—42,
Jan.
2024.
Abstract:
Worldwide, over 694 million people have been infected with SARS-CoV-2, with an estimated 55–60% of those infected developing COVID-19. Since the beginning of the pandemic in December 2019, different variants of concern have appeared and continue to occur. With the emergence of different variants, an increasing rate of vaccination and previous infections, the acute neurological symptomatology of COVID-19 changed. Moreover, 10–45% of individuals with a history of SARS-CoV-2 infection experience symptoms even 3 months after disease onset, a condition that has been defined as ‘post-COVID-19’ by the World Health Organization and that occurs independently of the virus variant. The pathomechanisms of COVID-19-related neurological complaints have become clearer during the past 3 years. To date, there is no overt — that is, truly convincing — evidence for SARS-CoV-2 particles in the brain. In this Review, we put special emphasis on discussing the methodological difficulties of viral detection in CNS tissue and discuss immune-based (systemic and central) effects contributing to COVID-19-related CNS affection. We sequentially review the reported changes to CNS cells in COVID-19, starting with the blood–brain barrier and blood–cerebrospinal fluid barrier — as systemic factors from the periphery appear to primarily influence barriers and conduits — before we describe changes in brain parenchymal cells, including microglia, astrocytes, neurons and oligodendrocytes as well as cerebral lymphocytes. These findings are critical to understanding CNS affection in acute COVID-19 and post-COVID-19 in order to translate these findings into treatment options, which are still very limited.
| DOI: | 10.1038/s41583-023-00769-8 |
| Datei: | https://www.nature.com/articles/s41583-023-00769-8 |
Abstract:
Worldwide, over 694 million people have been infected with SARS-CoV-2, with an estimated 55–60% of those infected developing COVID-19. Since the beginning of the pandemic in December 2019, different variants of concern have appeared and continue to occur. With the emergence of different variants, an increasing rate of vaccination and previous infections, the acute neurological symptomatology of COVID-19 changed. Moreover, 10–45% of individuals with a history of SARS-CoV-2 infection experience symptoms even 3 months after disease onset, a condition that has been defined as ‘post-COVID-19’ by the World Health Organization and that occurs independently of the virus variant. The pathomechanisms of COVID-19-related neurological complaints have become clearer during the past 3 years. To date, there is no overt — that is, truly convincing — evidence for SARS-CoV-2 particles in the brain. In this Review, we put special emphasis on discussing the methodological difficulties of viral detection in CNS tissue and discuss immune-based (systemic and central) effects contributing to COVID-19-related CNS affection. We sequentially review the reported changes to CNS cells in COVID-19, starting with the blood–brain barrier and blood–cerebrospinal fluid barrier — as systemic factors from the periphery appear to primarily influence barriers and conduits — before we describe changes in brain parenchymal cells, including microglia, astrocytes, neurons and oligodendrocytes as well as cerebral lymphocytes. These findings are critical to understanding CNS affection in acute COVID-19 and post-COVID-19 in order to translate these findings into treatment options, which are still very limited.
T. Donker,
A. Papathanassopoulos,
H. Ghosh,
R. Kociurzynski,
M. Felder,
H. Grundmann and
S. Reuter,Estimation of SARS-CoV-2 fitness gains from genomic surveillance data without prior lineage classification.
....
2024.
| DOI: | 10.1101/2024.01.08.24300976 |
A. Ranem,
C. González,
D. Santos,
A. Bucher,
A. Othman and
A. Mukhopadhyay,
"Continual atlas-based segmentation of prostate MRI"
in WACV,
2024.
| DOI: | 10.48550/arXiv.2311.00548 |
[en]
L. Petrov,
S. Brumhard,
S. Wisniewski,
P. Georg,
D. Hillus,
A. Hiller,
R. Astaburuaga-García,
N. Blüthgen,
E. Wyler,
K. Vogt,
H. Dey,
S. v. Stillfried,
C. Iwert,
R. D. Bülow,
B. Märkl,
L. Maas,
C. Langner,
T. Meyer,
J. Loske,
R. Eils,
I. Lehmann,
B. Ondruschka,
M. Ralser,
J. Trimpert,
P. Boor,
S. Bedoui,
C. Meisel,
M. A. Mall,
V. M. Corman,
L. E. Sander,
J. Röhmel and
B. Sawitzki,Rewired type I IFN signaling is linked to age-dependent differences in COVID-19,
Okt.
2024.
Abstract:
Advanced age is the most important risk factor for severe disease or death from COVID-19, but a thorough mechanistic understanding of the molecular and cellular underpinnings is lacking. Multi-omics analysis of samples from SARS-CoV-2 infected persons aged 1 to 84 years, revealed a rewiring of type I interferon (IFN) signaling with a gradual shift from signal transducer and activator of transcription 1 (STAT1) to STAT3 activation in monocytes, CD4+ T cells and B cells with increasing age. Diversion of interferon IFN signaling was associated with increased expression of inflammatory markers, enhanced release of inflammatory cytokines, and delayed contraction of infection-induced CD4+ T cells. A shift from IFN-responsive germinal center B (GCB) cells towards CD69high GCB and atypical B cells corresponded to the formation of IgA in children while complement fixing IgG was dominant in adults. Our data provide a mechanistic basis for inflammation-prone responses to infections and associated pathology during aging.
Abstract:
Advanced age is the most important risk factor for severe disease or death from COVID-19, but a thorough mechanistic understanding of the molecular and cellular underpinnings is lacking. Multi-omics analysis of samples from SARS-CoV-2 infected persons aged 1 to 84 years, revealed a rewiring of type I interferon (IFN) signaling with a gradual shift from signal transducer and activator of transcription 1 (STAT1) to STAT3 activation in monocytes, CD4+ T cells and B cells with increasing age. Diversion of interferon IFN signaling was associated with increased expression of inflammatory markers, enhanced release of inflammatory cytokines, and delayed contraction of infection-induced CD4+ T cells. A shift from IFN-responsive germinal center B (GCB) cells towards CD69high GCB and atypical B cells corresponded to the formation of IgA in children while complement fixing IgG was dominant in adults. Our data provide a mechanistic basis for inflammation-prone responses to infections and associated pathology during aging.
S. Winkelmann,
A. Korth,
B. Voss,
M. Nasr,
N. Behrend,
A. Pudszuhn,
V. Hofmann,
C. Maetzler,
A. Hermes,
C. Borzikowsky,
T. Bahmer,
W. Lieb,
S. Schreiber,
S. Störk,
F. Montellano,
M. Witzenrath,
T. Keil,
M. Krawczak,
M. Laudien,
On Behalf Of The Napkon Study Group and
C. Schendzielorz,
"Persisting chemosensory dysfunction in COVID-19 - a cross-sectional population-based survey Rhinology 2023",
Dez.
2023.
| DOI: | 10.4193/Rhin22.176 |
K. Appel,
R. Geisler,
D. Maier,
O. Miljukov,
S. Hopff and
J. J. Vehreschild,
"A Systematic Review of Predictor Composition, Outcomes, Risk of Bias, and Validation of Coronavirus Disease 2019 (COVID-19) Prognostic Scores",
Okt.
2023.
| DOI: | 10.1007/s15010-023-02043-6 |
K. Tilch,
S. Hopff,
K. Appel,
M. Kraus,
B. Lorenz-Depiereux,
L. Pilgram,
G. Anton,
S. Berger,
R. Geisler,
K. Haas,
T. Illig,
D. Krefting,
R. Lorbeer,
L. Mitrov,
M. Muenchhoff,
M. Nauck,
C. Pley,
J. Reese,
S. Rieg,
M. Scherer,
M. Stecher,
C. Stellbrink,
H. Valentin,
C. Winter,
M. Witzenrath and
J. J. Vehreschild,
"Ethical and coordinative challenges in setting up a national cohort study during the COVID-19 pandemic in GermanyShort- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19. BMC Medical Ethics",
Okt.
2023.
| DOI: | 10.1186/s12910-023-00959-0 |
D. Stahl,
A. Blumentritt,
E. Heim,
H. Valentin,
T. Bahls,
M. Bialke,
M. Kraus,
W. Hoffmann,
H. Rau and
L. Fiedler-Lacombe,
"Benefits of fully electronic consent management and consent collection via tablet PC in supporting time-critical pandemic research – the example of COVID-19-project NAPKON",
09
2023.
K. O. Yusuf,
I. Chaplinskaya-Sobol,
A. Schoneberg,
S. Hanss,
H. Valentin,
B. Lorenz-Depiereux,
S. Hansch,
K. Fiedler,
M. Scherer,
S. Sikdar,
O. Miljukov,
J. Reese,
P. Wagner,
I. Bröhl,
R. Geisler,
J. J. Vehreschild,
S. Blaschke,
C. Bellinghausen,
M. Milovanovic and
D. Krefting,
"Impact of Clinical Study Implementation on Data Quality Assessments - using Contradictions within Interdependent Health Data Items as a Pilot Indicator",
eingereicht bei GMDS Jahrestagung Heilbronn,
09
2023.
K. O. Yusuf,
I. Chaplinskaya-Sobol,
A. Schoneberg,
S. Hanss,
H. Valentin,
B. Lorenz-Depiereux,
S. Hansch,
K. Fiedler,
M. Scherer,
S. Sikdar,
O. Miljukov,
J. Reese,
P. Wagner,
I. Bröhl,
R. Geisler,
J. J. Vehreschild,
S. Blaschke,
C. Bellinghausen,
M. Milovanovic and
D. Krefting,
"Impact of Clinical Study Implementation on Data Quality Assessments – Using Contradictions within Interdependent Health Data Items as a Pilot Indicator, German Medical Data Sciences 2023 – Science close to People",
09
2023.
| DOI: | 10.3233/SHTI230707 |
F. Steinbeis,
C. Thibeault,
S. Steinbrecher,
Y. Ahlgrimm,
I. A. Haack,
D. August,
B. Balzuweit,
C. Bellinghausen,
S. Berger,
I. Chaplinskaya-Sobol,
O. Cornely,
P. Doeblin,
M. Endres,
C. Fink,
C. Finke,
S. Frank,
S. Hanss,
T. J. Hartung,
J. C. Hellmuth,
S. Herold,
P. Heuschmann,
J. Heyckendorf,
R. Heyder,
S. Hippenstiel,
W. Hoffmann,
S. U. Kelle,
P. Knape,
P. Koehler,
L. Kretzler,
D. M. Leistner,
J. Lienau,
R. Lorbeer,
B. Lorenz-Depiereux,
C. D. Lüttke,
K. Mai,
U. Merle,
L. Meyer-Arndt,
O. Miljukov,
M. Muenchhoff,
M. Müller-Plathe,
J. Neuhann,
H. Neuhauser,
A. Nieters,
C. Otte,
D. Pape,
R. M. Pinto,
C. Pley,
A. Pudszuhn,
P. Reuken,
S. Rieg,
P. Ritter,
G. Rohde,
M. Rönnefarth,
M. Ruzicka,
J. Schaller,
A. Schmidt,
S. Schmidt,
V. Schwachmeyer,
G. Schwanitz,
W. Seeger,
D. Stahl,
N. Stobäus,
H. C. Stubbe,
N. Suttorp,
B. Temmesfeld,
S. Thun,
P. Triller,
F. Trinkmann,
I. Vadasz,
H. Valentin,
M. J. G. T. Vehreschild,
C. Kalle,
M. Lilienfeld-Toal,
J. Weber,
T. Welte,
C. Wildberg,
R. Wizimirski,
S. Zvork,
L. E. Sander,
J. Vehreschild,
T. Zoller,
F. Kurth and
M. Witzenrath,
"Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP). Infection",
07
2023.
| DOI: | 10.1007/s15010-023-02057-0 |
Y. Shi,
R. Strobl,
C. Apfelbacher,
T. Bahmer,
R. Geisler,
P. Heuschmann,
A. Horn,
H. Hoven,
T. Keil,
M. Krawczak,
L. Krist,
C. Lemhöfer,
W. Lieb,
B. Lorenz-Depiereux,
R. Mikolajczyk,
F. Montellano,
J. Reese,
S. Schreiber,
N. Skoetz,
S. Störk,
J. J. Vehreschild,
M. Witzenrath,
E. Grill and
On Behalf Of The Napkon Study Group,
"Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort",
05
2023.
| DOI: | 10.1007/s15010-023-02043-6 |
D. Krefting,
G. Anton,
I. Chaplinskaya-Sobol,
S. Hanss,
W. Hoffmann,
S. Hopff,
M. Kraus,
R. Lorbeer,
B. Lorenz-Depiereux,
T. Illig,
C. Schäfer,
J. Schaller,
D. Stahl,
H. Valentin,
P. Heuschmann and
J. Vehreschild,
"The Importance of Being FAIR and FAST - The Clinical Epidemiology and Study Platform of the German Network University Medicine (NUKLEUS)",
05
2023.
| DOI: | 10.3233/SHTI230071 |
C. Dolch,
I. Bernemann,
B. Fösel,
S. Haag,
N. Klopp,
V. Kopfnagel,
A. Kühn-Steven,
S. Kunze,
B. Lorenz-Depiereux,
S. Mücke,
I. Ruhl,
M. Schieck,
G. Anton,
T. Illig and
M. Scheuner,
"Der NAPKON Bioprobenkern stellt sich vor",
05
2023.